WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:
A61N 5/06
A1
(11) International Publication Number: WO 90/10473
(43) International Publication Date: 20 September 1990 (20.09.90)

US

(21) International Application Number: PCT/US90/01225

(22) International Filing Date: 6 March 1990 (06.03.90)

(30) Priority data: 319,243 6 March 1989 (06.03.89)

477,141 8 February 1990 (08.02.90) US 477,142 8 February 1990 (08.02.90) US

(71) Applicant: THE UNITED STATES OF AMERICA, represented by THE SECRETARY, UNITED STATES DE-PARTMENT OF COMMERCE [US/US]; Washington, DC 20231 (US).


(72) Inventors: LEIGHTON, Stephen, B.; 9007 Woodland Drive, Silver Spring, MD 20910 (US). WEHR, Thomas, A.; 6028 Cheshire Drive, Bethesda, MD 20814 (US). ROSENTHAL, Norman, E.; 11110 Stephalee Lane, Rockville, MD 20852 (US). (74) Agents: OLIFF, James, A. et al.; Oliff & Berridge, 277 S. Washington Street, Alexandria, VA 22314 (US).

(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published

With international search report.

(54) Title: PORTABLE LIGHT DELIVERY SYSTEM



(57) Abstract

A device for delivering high intensity light to a patient's eyes for treating seasonal affective disorder and the like uses a point source of light such as a high intensity halogen or other incandescent bulb (14), and directs a large fraction of the light from the bulb (14) directly into the patient's eyes without focusing the light in such a way as to cause damage to the eye or discomfort to the patient. This is accomplished by the use of a positive lens (20) which focuses the light from the high intensity bulb (14) directly in front of the patient's eyes. The light appears to the patient to be coming from an area much larger than the actual point source, and hence is more comfortable for the patient. The patient is assured of receiving a significant dosage of light no matter which way he is directing his gaze.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mafi
BB ·	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Fesso	GB	United Kingdom	NL	Netherlands
		HU	Hungary	NO	Norway
BG	Bulgaria	iπ	Italy	RO	Romania
BJ	Benin		. •	SD	Sudan
BR	Brazil	JP.	Japan	SE	Sweden
CA	Canada	KP	Democratic People's Republic		
Œ	Central African Republic		of Korea	SN	Senegal
CG	Congo	KR	Republic of Korea	SU	Soviet Union
CH	Switzerland	u	Liechtenstein	\mathbf{m}	Chad
CM	Cameroon	LK	Sri Lanka	TG	Togo
DE	Germany, Federal Republic of	W	Luxembourg .	US	United States of Americ
nez	Denmark	MC	Могасо		

PORTABLE LIGHT DELIVERY SYSTEM

FIELD OF THE INVENTION

The present invention relates to improvements in phototherapy especially in the alleviation of winter depression and similar syndromes; and, more particularly, to an improved device for administering said phototherapy.

BACKGROUND OF THE INVENTION

Phototherapy is known especially for the treatment of winter depression, the "winter blues" and other
light responsive psychological and psychiatric conditions. Considerable research has been conducted over the
last several years on the effects of phototherapy on the
above-identified conditions, and a bibliography of
pertinent publications in this regard is provided below:

- 1. Lewy, A.J., Kern, H.A., Rosenthal, N.E., Wehr, T.A.: Bright artificial light treatment of a manic-depressive patient with a seasonal mood cycle. American Journal of Psychiatry, 139: 1496-1498, 1982.
- 2. Rosenthal, N.E., Lewy, A.J., Wehr, T.A., Kern, H.E.: Goodwin, F.K.: Seasonal cycling in a bioplar patient. Psychiatry Research, 8: 25-31, 1983.
- 3. Rosenthal, N.E., Sack, D.A., Gillin, J.C., Lewy, A.J., Goodwin, F.K., Davenport, Y., Newsome, D.A., Wehr, T.A.: Seasonal affective disorder: A description of the syndrome and preliminary findings with light therapy. Archives of General Psychiatry, 41: 72-80, 1984.
- 4. Rosenthal, N.E. Seasonal rhythms in mood and behavior, in Symposium: Endocrine Rhythms, and Behavior. Annals of the Royal College of Physicians and Surgeons of Canada, 17(7): 599-602, 1984.
- Rosenthal, N.E., Sack, D.A., Carpenter,
 C.J., Parry, B.L., Mendelson, W.B., Wehr,

20

5

25

30

WU 90/104/3

- T.A.: Antidepressant effects of light in seasonal affective disorder. American Journal of Psychiatry, 142: 163-170, 1985.
- 6. Rosenthal, N.E., Sack, D.A., Carpenter, C.J., Parry, B.L., Mendelson, W.B., Tamarkin, L., Wehr, T.A.: Seasonal affective disorder and phototherapy. Annals of the New York Academy of Sciences, 453: 260-269, 1985.
- 7. Wehr, T.A., Rosenthal, N.E., Sack, D.A., Gillin, J.C.: Antidepressant effects of sleep deprivation in bright and dim light. Acta Psychiatrica Scandinavica, 72: 161-165, 1985.
- 8. James, S.P., Wehr, T.A., Sack, D.A., Perry,
 B.L., Rosenthal, N.E.: Evening light treatment of seasonal affective disorder.
 British Journal of Psychiatry, 147: 424428, 1985.
- 9. Rosenthal, N.E., Carpenter, C.J., James, S.P., Parry, B.L., Rogers, S.L.B., Wehr, T.A.: Seasonal affective disorder in children and adolescents. American Journal of Psychiatry, 143: 356-358, 1986.
- 10. Rosenthal, N.E. Seasonal incidence of depression. Human Sexuality, 19(4): 125, 1985.
- 11. Jacobsen, F.M., Rosenthal, N.E. Seasonal affective disorder and the use of light as an antidepressant. Directions in Psychiatry, Vol. 6, Lesson 3: 1-7.
- 12. Hellekson, C.J., Kline, J.A., Rosenthal, N.E. Phototherapy for seasonal affective disorder in Alaska. Am. J. Psychiatry, 143(8): 1035-1037, 1986.
- 13. Rosenthal, N.E. Seasonal affective disorders: Seasonal energy syndrome? In

5

10

15⁻

20

25

30

		Reply. Arch. Gen. Psychiatry, 43: 188-189, 1986.
	14.	Rosenthal, N.E., James, S.P. Reply to
		letter on seasonal affective disorder. Br.
5		J. Psychiatry, 1148: 478-479, 1986.
	15.	Rosenthal, N.E., Heffernan, M.M. Bulimia,
		carbohydrate craving, and depression: a
		central connection? In Nutrition and the
		Brain, Wurtman, R.J., Wurtman, J.J. (eds.),
10		Raven Press, New York, pp. 139-166, 1986.
	16.	Brewerton, T.D., Heffernan, M.M.,
		Rosenthal, N.E. Psychiatric aspects of the
		relationship between eating and mood.
		Nutrition Reviews, 44: 78-88, 1986.
15	17.	Wehr, T.A., Sack, D.A., Jacobsen, F.,
		Tamarkin, L., Arendt, J., Rosenthal,
		N.E.: Timing of phototherapy and its
		effects on melatonin secretion are not
		critical for its antidepressant effect in
20		seasonal affective disorder.
	18.	Jacobsen, F.M., Wehr, T.A., Sack, D.A.,
		James, S.P., Perry, B.L., Rosenthal, N.E.
		Seasonal affective disorder in the work-
		place: implications for public health.
25		American Journal of Public Health, 77: 57-
		60, 1987.
	19.	Wehr, T.A., Skwerer, R.G., Jacobsen, F.M.,
		Sack, D.A., Rosenthal, N.E., Eye-versus.
		skin-phototherapy of seasonal affective
30		disorder. American Journal of Psychiatry,
		144: 753-766, 1987.
	20.	Parry, B.L., Rosenthal, N.E., James, S.P.,
		Wehr, T.A.: Treatment of a patient with
		seasonal premenstrual syndrome. American
35		Journal of Psychiatry, 144: 762-766, 1987.
	21.	Hellekson, C.J., Rosenthal, N.E. New light

on seasonal mood changes. Harvard Medical

- School Mental Health Letter, 3(10): 4-6, 1987.
- 22. James, S.P., Wehr, T.A., Sack, D.A., Rosenthal, N.E., Mendelson, W.B.: Experimental modalities in the treatment of seasonal and non-seasonal affective disorder. Biological Psychiatry, Shagass, C., Josiassen, R.C., Bridger, W.H., Weiss, K.J., Stoff, D., Simpson, G.M. (eds.), Elsevier, New York, 1985, pp. 144-146.
- 23. Rosenthal, N.E., Sack, D.A., Jacobsen, F.M., Parry, B.L., James, S.P., Tamarkin, L., Arendt, J., Wehr, T.A.: Consensus and controversy in seasonal affective disorder and phototherapy. Biological Psychiatry, Shagass, C., Josiassen, R.C., Bridger, W.H., Weiss, K.J., Stoff, D., Simpson, G.M. (eds.), Elsevier, New York, 1985, pp. 987-989.
- 24. Rosenthal, N.E., Sack, D.A., Jacobsen, F.M., Skwerer, R.G., Wehr, T.A. Seasonal affective disorder and light: past, present and future. Clinical Neuropharmacology, Bunney, W.E., Jr., costa, E., Potkin, S. (eds.), 9(4): 193-195, Raven Press, New York, 1986.
- 25. Rosenthal, N.E., Genhart, M., Jacobsen, F.M., Skwerer, R.G., Wehr, T.A. Disturbances of appetite and weight regulation in seasonal affective disorder. Annals of the New York Academy of Science, 499: 216-230, 1987.
- 26. Rosenthal, N.E., Sack, D.A., Wehr, T.A.: Seasonal effects on mood: The role of light, in Adelman, G. (ed.), Encyclopedia of Neuroscience, Vol. II, Birkhauser, Boston, pp. 586-588.

10

15

20

25

30

27. Jacobsen, F.M., Wehr, T.A., Skwerer, R.G., Sack, D.A., Rosenthal, N.E. Morning versus midday phototherapy of seasonal affective disorder. American Journal of Psychiatry, 144 (10): 1301-1305.

In brief summary, it has been discovered that sunlight and bright artifical light can suppress human melatonin secretion; that patients with seasonal mood cycle winter depression improved when hours of daylight lengthened with bright artificial light: depression, hypersomnia, overeating and carbohydrate craving were reduced with phototherapy; that bright light has a marked antidepressant effect whereas dim light does not; that seasonal affective disorder (SAD) is reduced by phototherapy with the results of reduced irritability, reduced fatigue, reduced sadness and improved sleep; that exposure from 2 to 6 hours per day of light at 2500 lux reduces SAD and acts as an antidepressant; that phototherapy may aid in the treatment of bulimia and seasonal premenstrual syndrome.

5

10

15

20

25

30

35

Normal room light is insufficient, and even a brightly lit room provides a light intensity of only about 500 lux, insufficient to have any phototherpeutic effect. Previously phototherapy for the above conditions has been effected by large cumbersome light emitting boxes which are not easily portable and which are inconvenient. The patient is effectively fixed to the equipment and cannot proceed with other activities. As phototherapy at 2500 lux must be carried out for at least one hour per day, and preferably at least two to four hours per day to be effective, prior light emitting boxes have proven very inconvenient for the patient.

A large body of prior art exists which, while not directly pertinent to the treatment of SAD and related disorders, is of background interest for reasons which will be apparent below. Thus, miners' lamps are known which comprise a head mounted torch or flashlight

10

15

20

25

30

35

for working in dark locales. In devices of this type, of course, the light is directed away from the eye rather than toward it.

The U.S. patent to Wyatt U.S. Patent No. 4,360,253 relates to a safety glass mounted test result indicator including a small light emitting diode mounted on a spectacle frame. Of course, the degree of light provided by such an LED is far too low to be effective for the treatment of SAD, and also the light provided is not a steady beam of light for any significant length of time. Also see the U.S. patents to Rinard et al, U.S. Patent No. 4,145,122; Scrivo et al, U.S. Patent No. 4,086,004; Hamilton et al, U.S. Patent No. 4,044,756; and Harding et al, U.S. Patent No. 3,621,836, all of which are also unsuitble for the treatment of SAD and related disorders for reasons similar to those pointed out above.

The U.S. patents to Giannone, U.S. Patent No. 4,057,054 and Rehm, U.S. Patent No. 3,883,225 relate to eye treatment devices incorporated into or onto spectacle-like frames. These also are unsuitable for the treatment of SAD not only because of the absence of providing a steady beam of light at a sufficient intensity for a sufficient period of time, but also because such devices suffer from the same defects as the light boxes, i.e. they do not permit the patient to proceed with other activities during the treatment.

Lastly, attention is invited to a letter to the editor appearing in Vol. 43 (Feb. 1986). Arch. Gen. Psychiatry, by Mueller and Davies. In this letter, the authors suggest treatment of SAD (referred to as seasonal energy syndrome) by the utilization of red-spectrum light in the fall-winter period as being superior to and more pratical than full spectrum light, and this is suitably achieved by the use of rose colored glasses. The use of spectacle frames or the like as a supporting means for light projecting means for directing a steady stream of light into the eye of the patient is not suggested.

One of the major problems in administering light therapy is the inconvenience of having to be close to a cumbersome and heavy light fixture. Until the invention of U.S. Parent Application Serial No. 167,252, filed March 11, 1988, there were no small portable fixtures being used for phototherapy. Although a device involving a few incandescent plant lights has been recommended for the treatment of SAD, there have been no previous reports of devices which are portable and worn or placed close to the eyes. This aspect has been addressed in U.S. Patent Application Serial No. 215,293, filed July 5, 1988.

5

10

15

SUMMARY OF THE INVENTION

It is, accordingly, an object of the invention to overcome deficiencies in the prior art, such as indicated above.

It is another object of the invention to provide for the more convenient treatment of SAD and related disorders.

It is still another object of the present invention to administer light in a convenient and portable way
to individuals with winter depression, the "winter blues"
and other light responsive psychological and psychiatric
conditions, as well as to enhance immune function.

It is a further object to provide a device for shining light into an eye of a patient for the treatment of depression or the like.

It is still a further object of the invention to provide for the use of a head mounted lamp in the alleviation of sleep problems, depression, jet lag, winter blues, and to affect changes in the lymphocytes so as to affect the functional immune system.

Another object of the present invention is to deliver high intensity light to a patient's eyes, for treating seasonal effective disorder and other conditions that may be so treated, and in a manner which is both comfortable to the patient and involves improved efficiency and reduced battery drain.

10

15

20

25

35

. :

The present improvement is based on the provision of an improved light delivery system, and desirably utilizes a high intensity halogen or other incandescent bulb as well as means for directing a large fraction of the light from the bulb directly into the patient's eye, without focusing the light in a way that could cause damage to the eye or to the patient. By the proper. selection of such a light directing means, including an . appropriate means for focusing the beam of light in front: of the patient's eye such as a positive or convex lens, preferably of the Fresnel type, the light appears to the patient to be coming from an area much larger than the actual point source, and hence is more comfortable to The patient is assured of receiving a significant dosage of light no matter which way he is directing his qaze.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects and the nature and advantages of the present invention will be more apparent from the following detailed description of embodiments, taken in conjunction with the drawing wherein:

Figure 1 schematically shows an optical arrangement for a portable light dosage or delivery system according to the present invention; and

Figures 2-4 schematically show alternative embodiments.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In earlier embodiments such as those disclosed in the aforementioned parent U.S. applications, light dosage systems are proposed which use extended fluorescent tubes, or point sources such as incandescent bulbs as sources. Where fluorescent tubes are used as sources, these use more power because the light cannot be focused efficiently, and much of the light is wasted by going in directions other than into the eyes. Where incandescent bulbs are used, the light may not be focused at all or may be focused into a parallel beam of relatively large

diameter by the use of a parabolic reflector, such as the type used in flashlights, in which case the light appears to come from only one direction; again, much of the light. is wasted and is not directed into the eye. Alternatively, the light may be focused into a small parallel beam by the use of such a parabolic reflector, in which case the light will appear to the patient to be uncomfortably bright.

The present invention uses a focusing means such as a positive lens, preferably of the Fresnel type, to 10 direct the light in a cone toward the eye. appears to come from a large source, and so it is not too bright and therefore it is comfortable to the patient. The patient is assured of receiving a significant dosage 15 of light no matter which way he is directing his gaze. The light is efficiently directed into the eve.

With reference to Figure 1, there shown is such a light delivery system including a system supporting means 10 in the form of a helmet, visor, cap, hat or headband such as shown in the aforementioned parent applications. The helmet 10 or the like supports a pair, one for each eye, of optical assemblies 12 through suitable means 14 as schematically illustrated. The optical. assemblies 12 are positioned in front of and above the eyes as disclosed in the aforementioned parent applica-25 tions.

20

Each assembly 12 contains a point source 14 of light, preferably a small, high efficiency halogen bulb, although any type of incandescent bulb, desirably of the 30 high intensity type, can be used. A suitable housing is provided for the bulb 14, including a bottom support wall 16 for the bulb 14 and its socket, a top wall 18, and preferably a pair of side walls (not shown). Forming the front wall of the housing, or at least a part of the 35 front wall, is a positive (convex) lens 20 of high numerical aperture (desirably at least 0.5 and preferably 0.8 or more - these values are unitless, and are obtained by

ķ

Ĉ

5

10

15

20

35

the formula d/2f where d is the diameter of the lens and f is its focal length.), so that such positive lens 20 is placed between the eye and the bulb 14. A concave spherical mirror 22 desirably comprises at least a portion of a rear wall of the housing to redirect light emitted in that direction back toward the lens 20. The spherical mirror 22 is desirably positioned with its center of curvature coincident with the filament of the bulb 14.

The positioning of the optical elements, and especially the convex lens 20, is very important. Thus, the focal length of the convex lens 20 and its position relative to the bulb 14 and the eye are so chosen that the image of the light source is focused in the front of the eye, e.g. 1-2 cm. in front of the eye. In this way it is ensured that a damaging or uncomfortable concentration of light energy cannot occur within the eye. The light appears to the user to be coming from the entire lens, and hence the light is not unacceptably bright. On the otherhand, almost all the light is directed toward the eye so that improved efficiency is obtained adding substantial battery life.

The Fresnel lens 20 and the mirror 22, as well as other parts of the housing, may be formed of light-weight plastic material. If sidewalls are provided for the housing, these may be opaque or translucent, and they may be provided with reflective internal surfaces. The lower and upper walls 18 may also be formed of opaque plastic with reflective inner surfaces.

As disclosed in the parent U.S. applications, 30 the bulb 14 is powered by a suitable battery or battery pack, and appropriate electrical leads are provided along with, if desired, appropriate auxiliary elements as disclosed in parent application Serial No. 167,252.

Figures 2-4 show additional embodiments which function on the same principle, but which use concave mirrors to focus the beam of light in front of the patient's eye in order to accomplish the same objective

as pointed out above.

Of the embodiments of Figures 2 and 3 using reflective mirrors instead of a positive lens, that of Figure 2 is preferred. In this embodiment, the reflective mirror 50 forms part of an ellipse having the focal 5 points f and f'. A high intensity light source 54 is placed at the focal point f. The device is so placed from the eye that the second focal point f' is located in front of the eye, e.g. 1-2 cm. in front of the eye so as to provide the same effect as mentioned above with regard 10 to the description of the Figure 1 embodiment. vent light from the light source 54 going directly to the eye, which would be uncomfortable for the patient, a suitable blocking means 56 is provided, which blocking 15 means may also serve as a support for the high intensity light source 54. The blocking means 56 is preferably a small spherical mirror so that it will reflect light back to the ellipsoidal mirror 50, although the blocking means could be a mirror of another shape or it could be a 20 translucent diffuser or even an opaque block. shperical mirror 56 is preferred because it makes most efficient use of the generated light, and it will be understood that the curvature of the spherical mirror should be less than a hemisphere with the light source 54 25 being desirably at its focal point. In any event, the blocking means 56 should be sufficiently wide so as to shield the light source 54 from direct observation by the patient.

mirror 60 is a paraboloidal mirror or a spherical mirror, especially a spherical mirror approximating an ellipsoid, the mirror 60 having a focal point f. In this case, the location of the light source 54 is not at the focal point f, but instead is closer to the eye than the focal point f. If the light source 54 were placed at the focal point f, then the reflected rays leaving the mirror 60 would be parallel as in a flashlight or an automobile headlamp,

10

15

20

25

EULI UUZUI VAAA

5

and would not focus in front of the eye as required according to the present invention. As in the other embodiments, the elements must be selected so that the light will focus in front of the patient's eyes for the reasons explained above.

Figure 4 schematically shows a possible structure for effecting the construction of Figures 2 and 3, in a form of a sealed-beam lamp similar to a sealed beam headlamp for an automobile, and formed of a single structural unit including an ellipsoidal, spherical or paraboloidal mirror 70 having a focal point f, an incandescent filament 74 serving as a light source and supported on a support and blocking means 76, and an annular transparent portion 78 through which the reflected light is passed so as to focus in front of the eye as shown in Figures 2 and 3.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current know-ledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation.

WHAT IS CLAIMED IS:

10

15

35

1. A device for shining light into an eye for the treatment of depression, comprising:

support means for mounting said device on the head of a patient;

light generating means for generating a steady beam of light at the eye such that said beam applies an intensity of 1,000 to 10,000 lux to the eye, said light generating means being supported by said support means; and

light projecting means, supported by said support means, for directing said steady beam of light into the eye of the patient, said light projecting means comprising means for focusing said light in the form of a cone from said light generating means immediately in front of the eye of the patient.

- 2. A device according to claim 1, wherein said means for focusing said light comprises a positive lens.
- 3. A device according to claim 2, wherein said positive lens is a convex lens.
 - 4. A device according to claim 2, wherein said positive lens is a Fresnel lens.
- 5. A device in accordance with claim 2, wherein said light projecting means further comprises a

 25 spherical mirror disposed behind said light generating means.
 - 6. A device in accordance with claim 1, wherein said light generating means is a high intensity incandescent bulb.
- 7. A device in accordance with claim 1, wherein said light generating means is a halogen bulb.
 - 8. A device in accordance with claim 1, wherein said means for focusing said light comprises an
 ellipsoidal mirror, said light generating means being
 located at a focal point of said ellipsoidal mirror, said
 ellipsoidal mirror being located relative to the eye such
 that another focal point of said ellipsoidal mirror is in

10

15


front of the eye of the patient.

9. A device according to claim 8, further comprising a blocking means located between said light generating means and the eye of the patient.

}

Š

- 10. A device in accordance with claim 9, wherein said light blocking means comprises a mirror to direct light back to said ellipsoidal mirror.
- 11. A device in accordance with claim 1, wherein said means for focusing said light comprises a paraboloidal or spherical mirror having a focal point, said
 light generating means being located between said focal
 point and the eye of the patient.
- 12. A device according to claim 11, further comprising a blocking means located between said light generating means and the eye of the patient.
- 13. A device in accordance with claim 12, wherein said light blocking means comprises a mirror to direct light back to said paraboloidal or spherical mirror.



•

I. CLAS	SIFICATIO	N OF SUBJECT MATTER (If several class		PCT/US90/01225						
I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) According to International Patent Classification (IPC) or to both National Classification and IPC TPC: (5): A61N 5/06										
220 (3). 11011 3/00										
U S		128/380	•							
II. FIELDS SEARCHED										
Minimum Documentation Searched 7 Classification System										
Ciassilicat	on System		Classification Symbols							
US 128/395,396,397,398,23 353/81 351/213,158,20			24.1,380 362/103,104,1 ,245,221,216,233	105,106,107,32						
Documentation Searched other than Minimum Documentation to the Extent that such Documents are included in the Fields Searched **										
III. DOCUMENTS CONSIDERED TO BE RELEVANT 9										
Category •										
		on of Document, 11 with indication, where app	propriate, of the relevant passages 12	Relevant to Claim No. 13						
A,P	US,A	4,858,609 (COLE) See Entire Document	22 August 1989	1-13						
A	US,A	4,057,054 (GIANNONE) See Entire Document	08 November 1977	1-13.						
A	US,A	3,621,838 (HARDING E See Entire Document	I. AL). 23 November: 1971	1-13						
A	US,A	4,553,534 (STIEGLER) See Entire Document	19 November 1985	1-13.						
A	SU,A	430,840 (AKHUTIN) See Entire Document	12 April 1974	1-13						
A	N	The Chicago Tribune, Richard Phillips, "Let	11 December 1985 the Sun Shine"	1-13						
		f cited documents: 10	"T" later document published after th	a international filing date						
COUR	ngeres fo be	g the general state of the art which is not of particular relevance	cited to understand the principle	T with the enclines on his						
"E" earli filine	er document date	but published on or after the international	"X" document of particular relevans	et the claimed investion						
"L" document which may throw doubte on printing desired a cannot be considered novel or cannot be considered										
citat	on or other to	establish the publication date of another special reason (as specified)	"Y" document of particular relevant cannot be considered to involve a	e; the claimed invention						
QUIT	r means	ng to an oral disclosure, use, exhibition or	document is combined with one	or more other such docu-						
"P" docu	ment publish	ed prior to the international filing date but	ments, such combination being o in the art.							
later than the priority date claimed "å" document member of the same patent family IV. CERTIFICATION										
		pletion of the International Search	D-1							
	April 1		Oate of Mailing of this International Search Report							
International Searching Authority Signature of Authorized Officer										
ISA	/US		Mark S. Graham							